Latest Northwest Biotherapeutics Stories
NW Bio Exhibit Will Describe DCVax Technology and Clinical Trial Progress at Annual Meeting of Over 25,000 Oncologists BETHESDA, Md., May 23, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it will use its exhibit at this year's American Society Of Clinical Oncology (ASCO) meeting in Chicago to highlight its leadership role in immune...
Up To 30 European Sites To Join 46 Active Sites In The US BETHESDA, Md., May 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®)-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax(®)-L for brain cancer has been initiated at King's College Hospital in the UK. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) This is one of the first...
BETHESDA, Md., May 3, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today the availability on the web of several interviews of their CEO Linda Powers on the floor of the New York Stock Exchange on May 1, 2013 by FOX Business News (FOX), the Huffington Post, and the International Business Times, amongst others. (Logo:...
BETHESDA, Md., April 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that on April 17, 2013, it entered into an agreement with one healthcare-dedicated institutional investor for a registered direct placement of $10 million of common stock at the closing market price of $3.90 per share. (Logo:...
Unprecedented Results Compared With Current Standard of Care BETHESDA, Md., April 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme (GBM) brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the...
Trial Sites Will Receive Support from UK Health System BETHESDA, Md., April 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the Company's Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer has been "adopted" as a national priority trial in the UK, under the "adoption" program managed by the National Institute for...
BETHESDA, Md., April 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, filed its annual report on Form 10K today, reporting its financial results for the year ended December 31, 2012. The report also shows strong progress in all areas of the Company's operations, enhancing the Company's leadership position in immune therapies for cancer. (Logo:...
CEO Will Discuss Key Strengths and Progress, Announce New Developments BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company's Chairman and Chief Executive Officer, will be presenting at the 25(th) Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Ritz-Carlton, Laguna...
Next Generation Technology Already In DCVax®-Direct; Will Be Applicable To All DCVax® Products BETHESDA, Md., March 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells. The cells produced through these processes are much more...
Approvals Expanding the Scope of German Manufacturing Are Key Steps BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the Company has taken a key step in building Europe-wide arrangements for manufacturing and distribution of DCVax. This represents a major area of competitive differentiation and strength for NW Bio....
